Post-transplant infections: single center experience from the developing world

International Journal of Infectious Diseases

Volumn 12, Issue 2, 2008, Pages 203-214

  Ullah, Khalil ^a   Raza, Shahid ^a   Ahmed, Parvez ^a   Chaudhry, Qamar un Nisa ^a   Satti, Tariq Mahmood ^a   Ahmed, Suhaib ^b   Mirza, Sajjad Hussain ^b   Akhtar, Fahim ^b   Kamal, Khalid ^a   Akhtar, Farrukh Mahmood ^a  

^a National Institute of Heart Diseases National University of Medical Sciences   (Pakistan)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (Pakistan)

Author keywords

Allogeneic stem cell transplants; Antimicrobials; Infections

Indexed keywords

CYCLOSPORIN; FOLINIC ACID; HLA ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHOTREXATE; PREDNISOLONE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; ASPERGILLOSIS; BACTERIUM CULTURE; BETA THALASSEMIA; BLOOD GROUP; BONE MARROW; BONE MARROW TRANSPLANTATION; CHILD; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ASSESSMENT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DEATH; DEVELOPING COUNTRY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GRAFT INFECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MORTALITY; PAKISTAN; PROPHYLAXIS; SEPTICEMIA; STEM CELL; TUBERCULOSIS; VIROLOGY; VIRUS INFECTION;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; CHILD; CHILD, PRESCHOOL; DEVELOPED COUNTRIES; FEMALE; FUNGI; GRAFT VS HOST DISEASE; GRAM-NEGATIVE BACTERIA; HEMATOLOGIC DISEASES; HOSPITALS, MILITARY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PAKISTAN; POSTOPERATIVE COMPLICATIONS; PROPORTIONAL HAZARDS MODELS; SIBLINGS; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; VIRUSES;

EID: 39049160106     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2007.06.012     Document Type: Article

References (44)

1. Loberiza Jr. F. Reports on state of the art in blood and marrow transplantation-part I of the IBMTR/ABMTR summary slides with guide. IBMTR/ABMTR Newsletter 10 (2003) 7-10. http://www.cibmtr.org/PUBLICATIONS/NEWSLETTER/2003Nov.pdf Available at: http://www.cibmtr.org/PUBLICATIONS/NEWSLETTER/2003Nov.pdf (accessed August 2007)
2. Hayes-Lattin B., Leis J.F., and Maziarz R.T. Isolation in the allogeneic transplant environment: how protective is it?. Bone Marrow Transplant 36 (2005) 373-381
3. Einsele H., Bertz H., Beyer J., Kiehl M.G., Runde V., Kolb H.J., et al. Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies. Ann Hematol 82 (2003) S175-S185
4. McCann S., Byrne J.L., Rovira M., Shaw P., Ribaud P., Sica S., et al. Outbreaks of infectious diseases in stem cell transplant units: a silent cause of death for patients and transplant programmes. Bone Marrow Transplant 33 (2004) 519-529
5. Pittet D., Li N., Woolson R.F., and Wenzel R.P. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. Clin Infect Dis 24 (1997) 1068-1078
6. Marr K.A., Seidel K., Slavin M.A., Bowden R.A., Schoch H.G., Flowers M.E., et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long term follow-up of a randomized, placebo-controlled trial. Blood 96 (2000) 2055-2061
7. Sepkowitz K.A. Antibiotic prophylaxis in patients receiving hematopoietic stem cell transplant. Bone Marrow Transplant 29 (2002) 367-371
8. Engels E.A., Lau J., and Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 16 (1998) 1179-1187
9. Ljungman P., Reusser P., de la Camara R., Einsele H., Engelhard D., Ribaud P., et al. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 33 (2004) 1075-1081
10. Ljungman P., Griffiths P., and Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34 (2002) 1094-1097
11. Ljungman P., De La Camara R., Milpied N., Volin L., Russell C.A., Crisp A., et al. A randomized study of valaciclovir as prophylaxis against CMV reactivation in allogeneic bone marrow transplant recipients. Blood 73 (2002) 930-936
12. Glucksberg H., Storb R., Fefer A., Buckner C.D., Neiman P.E., Clift R.A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 18 (1974) 295-304
13. Fujimaki K., Maruta A., Yoshida M., Kodama F., Matsuzaki M., Fujisawa S., et al. Immune reconstitution assessed during five years after allogeneic bone marrow transplantation. Bone Marrow Transplant 27 (2001) 1275-1281
14. Hoyle C., and Goldman J.M. Life-threatening infections occurring more than 3 months after BMT. 18 UK Bone Marrow Transplant Teams. Bone Marrow Transplant 14 (1994) 247-252
15. Wingard J.R. Advances in the management of infectious complications after bone marrow transplantation. Bone Marrow Transplant 6 (1990) 371-383
16. Wingard J.R. Opportunistic infections after blood and bone marrow transplantation. Clin Infect Dis 1 (1999) 3-20
17. Collin B.A., Leather H.L., Wingard J.R., and Ramphal R. Evolution, incidence and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis 33 (2001) 947-953
18. Wang C.C., Mattson D., and Wald A. Corynebacterium jeikeium bacteremia in bone marrow transplant patients with Hickman catheters. Bone Marrow Transplant 27 (2001) 445-449
19. Ghosh K., Shenoy A.K., and Al-Mahrooqi Z. Bacteriological infections during the first hundred days of allogeneic bone marrow transplantation-experience from Oman. J Assoc Physicians India 50 (2002) 910-912
20. Arns da Cunha C., Weisdorf D., Shu X.O., DeFor T., Pastor III J.D., and Johnson J.R. Early Gram-positive bacteremia in BMT recipients: impact of three different approaches to antimicrobial prophylaxis. Bone Marrow Transplant 21 (1998) 173-180
21. George B., Mathews V., Viswabandya A., Srivastava A., and Chandy M. Infections in children undergoing allogeneic bone marrow transplantation in India. Pediatr Transplant 10 (2006) 48-54
22. Kindler T., Schindel C., Brass U., and Fischer T. Fatal sepsis due to Mycobacterium tuberculosis after allogeneic bone marrow transplantation. Bone Marrow Transplant 27 (2001) 217-218
23. Lee J., Lee M.H., Kim W.S., Kim K., Park S.H., Lee S.H., et al. Tuberculosis in hematopoietic stem cell transplant recipients in Korea. Int J Hematol 79 (2004) 185-188
24. Arslan O., Gurman G., Dilek I., Ozcan M., Koç H., Ilhan O., et al. Incidence of tuberculosis after bone marrow transplantation in a single center from Turkey. Haematologia (Budap) 29 (1998) 59-62
25. Ku S.C., Tang J.L., Hsueh P.R., Luh K.T., Yu C.J., and Yang P.C. Pulmonary tuberculosis in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 27 (2001) 1293-1297
26. George B., Mathews V., Srivastava V., Srivastava A., and Chandy M. Tuberculosis among allogeneic bone marrow transplant recipients in India. Bone Marrow Transplant 27 (2001) 973-975
27. Chandy M., Srivastava A., Dennison D., Mathews V., and George B. Allogeneic bone marrow transplantation in the developing world: experience from a center in India. Bone Marrow Transplant 27 (2001) 785-790
28. De Castro N., Neuville S., Sarfati C., Ribaud P., Derouin F., Gluckman E., et al. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant 36 (2005) 879-883
29. Safdar A., Van Rhee F., Henslee-Downey J.P., Singhal S., and Mehta J. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant 28 (2001) 873-878
30. Mehta P., Augustson B., Krishnamurthy S., Jacob A., Roy D., Olliff J., et al. Successful allogeneic haematopoietic stem cell transplantation in patients with poor-risk leukaemia and prior invasive fungal infection. Bone Marrow Transplant 34 (2004) 825-826
31. Simoneau E., Kelly M., Labbe A.C., Roy J., and Laverdière M. What is the clinical significance of positive blood cultures with Aspergillus spp in hematopoietic stem cell transplant recipients? A 23 year experience. Bone Marrow Transplant 35 (2005) 303-306
32. Girmenia C., Nucci M., and Martino P. Clinical significance of Aspergillus fungaemia in patients with haematological malignancies and invasive aspergillosis. Br J Haematol 114 (2001) 93-98
33. Lin S.J., Schranz J., and Teutsch S.M. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32 (2001) 358-364
34. Offner F., Cordonnier C., Ljungman P., Prentice H.G., Engelhard D., De Bacquer D., et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 26 (1998) 1098-1103
35. Kontoyiannis D.P., Sumoza D., Tarrand J., Bodey G.P., Storey R., and Raad I.I. Significance of aspergillemia in patients with cancer: a 10-year study. Clin Infect Dis 31 (2000) 188-189
36. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 (2002) 408-415
37. Patterson T.F., Kirkpatrick W.R., White M., Hiemenz J.W., Wingard J.R., Dupont B., et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 79 (2000) 250-260
38. Cordonnier C., Maury S., Pautas C., Bastié J.N., Chehata S., Castaigne S., et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 33 (2004) 943-948
39. Weinberger M., Sacks T., Sulkes J., Shapiro M., and Polacheck I. Increasing fungal isolation from clinical specimens: experience in a university hospital over a decade. J Hosp Infect 35 (1997) 185-195
40. George B., Mathew V., Srivastava A., and Chandy M. Infections among allogeneic bone marrow transplant recipients in India. Bone Marrow Transplant 33 (2004) 311-315
41. Wingard J.R., Piantadosi S., Burns W.H., Zahurak M.L., Santos G.W., and Saral R. Cytomegalovirus infections in bone marrow transplant recipients given intensive cytoreductive therapy. Rev Infect Dis 12 Suppl 7 (1990) S793-S804
42. Reusser P., Einsele H., Lee J., Volin L., Rovira M., Engelhard D., et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 99 (2002) 1159-1164
43. Ljungman P., Deliliers G.L., Platzbecker U., Matthes-Martin S., Bacigalupo A., Einsele H., et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 97 (2001) 388-392
44. Ljungman P., Engelhard D., de la Cámara R., Einsele H., Locasciulli A., Martino R., et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 35 (2005) 737-746